PMID- 1561007
OWN - NLM
STAT- MEDLINE
DCOM- 19920513
LR  - 20131121
IS  - 0031-3998 (Print)
IS  - 0031-3998 (Linking)
VI  - 31
IP  - 3
DP  - 1992 Mar
TI  - Group B streptococcal sepsis in piglets: effect of combined pentoxifylline and 
      indomethacin pretreatment.
PG  - 222-7
AB  - Group B streptococcus (GBS), a common neonatal gram-positive pathogen, causes 
      similar pathophysiology in human newborns and neonatal animal models of sepsis. 
      Animal models of GBS sepsis demonstrate a two-phase response: 1) an acute phase 
      (less than 1 h) of increased pulmonary artery pressure (Ppa) and reduced arterial 
      oxygen pressure (PaO2) that is associated with increased serum thromboxane B2 
      (TxB2) and 2) a late phase (2-4 h) of persistently increased Ppa and reduced 
      PaO2, reduced systemic arterial pressure, and progressive fall in cardiac output 
      that is associated with increased serum TxB2, 6-keto-prostaglandin F1 alpha 
      (6-keto-PGF1 alpha), and tumor necrosis factor-alpha (TNF alpha). We hypothesized 
      that pretreatment of piglets with both pentoxifylline (PTF), an inhibitor of TNF 
      alpha production and activity, and indomethacin (INDO) would 1) inhibit 
      GBS-induced TxB2, 6-keto-PGF1 alpha, and TNF alpha and 2) prevent both the acute- 
      and late-phase physiologic responses of GBS sepsis. Combined PTF and INDO 
      pretreatment of anesthetized, mechanically ventilated piglets infused with GBS 
      (1.25 x 10(9) colony forming units/kg/h) for 4 h prevented GBS-induced increases 
      in Ppa at 1 h (GBS + PTF + INDO: 1.8 +/- 0.07 kPa versus GBS alone: 4.7 +/- 0.1 
      kPa) and markedly attenuated increases in Ppa at 4 h (GBS + PTF + INDO: 2.1 +/- 
      0.1 kPa versus GBS alone: 4.4 +/- 0.1 kPa).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Gibson, R L
AU  - Gibson RL
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle 
      98195.
FAU - Truog, W E
AU  - Truog WE
FAU - Henderson, W R Jr
AU  - Henderson WR Jr
FAU - Redding, G J
AU  - Redding GJ
LA  - eng
GR  - HL30542/HL/NHLBI NIH HHS/United States
GR  - HL39157/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pediatr Res
JT  - Pediatric research
JID - 0100714
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - SD6QCT3TSU (Pentoxifylline)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - Hemodynamics/drug effects
MH  - Indomethacin/*administration & dosage
MH  - Pentoxifylline/*administration & dosage
MH  - Pulmonary Circulation/drug effects
MH  - Pulmonary Gas Exchange/drug effects
MH  - Streptococcal Infections/*drug therapy/physiopathology
MH  - *Streptococcus agalactiae
MH  - Swine
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/biosynthesis
EDAT- 1992/03/11 19:15
MHDA- 2001/03/28 10:01
CRDT- 1992/03/11 19:15
PHST- 1992/03/11 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1992/03/11 19:15 [entrez]
AID - 10.1203/00006450-199203000-00006 [doi]
PST - ppublish
SO  - Pediatr Res. 1992 Mar;31(3):222-7. doi: 10.1203/00006450-199203000-00006.